ESCORT
Regimen
- Experimental
- camrelizumab
- Control
- investigator-choice chemotherapy (docetaxel or irinotecan)
Population
Advanced or metastatic ESCC progressed after or intolerant to first-line therapy
Key finding
mOS 8.3 vs 6.2 mo (HR 0.71, 95% CI 0.57-0.87, p=0.001); Chinese-only population; taxane/irinotecan control
Source: PMID 32416073